retatrutide weight loss trial data Eli Lilly infiltrates anti-obesity market as Phase III for begins Retatrutide, an experimental drug currently

Diabetes 2008;57:696705 [DOI] [PubMed] [Google Scholar] 39.Chaiteerakij R, Yang JD, Harmsen WS, et al

Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even if Unaffordable

The Phase 3 results confirm that Retatrutide at 12mg produces the highest weight loss ever recorded in an obesity medication trial, with nearly 29% average reduction at 68 weeks

It may not suit people looking for a weight loss plan that focuses more on lifestyle changes, fitness, and nutrition

Fibrosis stage matters because it helps estimate future risk

Once FDA-approved (expected 2027), the commercial price will likely be $1,0001,500/month before insurance, based on tirzepatide and semaglutide pricing